• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

American College of Cardiology 71st Scientific Sessions: Science Preview, April 4, 2022

Slideshow
Conference|ACC

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

On the final day of ACC 2022, check out late-breaking clinical trials during 3 different sessions.

A few higlights: Edoxaban vs DAPT post-TAVR, finerenone and cardiorenal outcomes in special CVD populations, canakinumab and residual inflammatory risk, and a report on an international ACC program to improve treatment for STEMI.

Saturday, April 2, 2022 Late Breaking Clincial Trials

Sunday, April 3, 2022 Late Breaking Clincial Trials

More News from ACC on Patient Care

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Untreated, New-Onset Hypertension Tied to Higher Risk of Uterine Fibroids in Women / Image credit: ©AGPhotography/AdobeStock

Untreated, New-Onset Hypertension Tied to Higher Risk of Uterine Fibroids in Women

April 19th 2024
Article

Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data / Image credit: ©Vasiliy/AdobeStock

Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data

April 9th 2024
Article

ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Bempedoic Acid Reduces CV Risk in Statin-Intolerant Individuals: Daily Dose / image credit: ©New Africa/AdobeStock

Bempedoic Acid Reduces CV Risk in Latinx Population with Statin-Intolerance: Daily Dose

April 5th 2024
Article

Your daily dose of the clinical news you may have missed.

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose / image credit: ©New Africa/AdobeStock

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose

April 4th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.